Chimovits Erez
Reporting owner on Forms 3, 4 and 5, CIK 1706399.
Chimovits Erez reported on 1 issuer in 1 filing, the latest a Form 4 filed 2026-09-30.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| ADARx Pharmaceuticals, Inc. CIK 1802369 | director | 1 | 2026-09-30 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +7,127,019 | 7,127,019 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +1,333,975 | 8,460,994 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +513,067 | 8,974,061 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | C converted | +256,448 | 9,230,509 | Form 4 | |
| ADARx Pharmaceuticals, Inc. Common Stock | 2026-09-28 | P bought | +61,516 | $17 | 9,292,025 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series A Preferred Stock, derivative | 2026-09-28 | C converted | -7,127,019 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series B Preferred Stock, derivative | 2026-09-28 | C converted | -1,333,975 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series B-1 Preferred Stock, derivative | 2026-09-28 | C converted | -513,067 | $0 | 0 | Form 4 |
| ADARx Pharmaceuticals, Inc. Series C Preferred Stock, derivative | 2026-09-28 | C converted | -256,448 | $0 | 0 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0000947871-26-000912 | ADARx Pharmaceuticals, Inc. | 2026-09-30 |